Credit Agricole S A purchased a new position in shares of Spark Therapeutics Inc (NASDAQ:ONCE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 9,830 shares of the biotechnology company’s stock, valued at approximately $814,000.

Several other institutional investors also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Spark Therapeutics by 2.6% in the second quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock worth $458,206,000 after buying an additional 142,428 shares during the period. BlackRock Inc. boosted its position in shares of Spark Therapeutics by 8.7% in the second quarter. BlackRock Inc. now owns 2,869,232 shares of the biotechnology company’s stock worth $237,459,000 after buying an additional 229,786 shares during the period. Swiss National Bank boosted its position in shares of Spark Therapeutics by 6.6% in the second quarter. Swiss National Bank now owns 58,300 shares of the biotechnology company’s stock worth $4,825,000 after buying an additional 3,600 shares during the period. American Century Companies Inc. raised its holdings in shares of Spark Therapeutics by 208.0% during the second quarter. American Century Companies Inc. now owns 65,203 shares of the biotechnology company’s stock worth $5,396,000 after acquiring an additional 44,034 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Spark Therapeutics by 9.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 165,264 shares of the biotechnology company’s stock worth $13,678,000 after acquiring an additional 13,894 shares in the last quarter.

NASDAQ ONCE opened at $62.36 on Friday. Spark Therapeutics Inc has a fifty-two week low of $41.06 and a fifty-two week high of $96.59. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -8.17 and a beta of 2.39.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.34). Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. The company had revenue of $25.19 million for the quarter, compared to the consensus estimate of $29.44 million. equities research analysts anticipate that Spark Therapeutics Inc will post -1.66 EPS for the current year.

ONCE has been the subject of several recent research reports. Leerink Swann reiterated a “market perform” rating and set a $55.00 price objective on shares of Spark Therapeutics in a report on Monday, May 7th. Cantor Fitzgerald set a $103.00 price objective on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 8th. Mizuho reiterated a “buy” rating and set a $91.00 price objective on shares of Spark Therapeutics in a report on Tuesday, May 8th. Cowen reiterated a “buy” rating and set a $85.00 price objective on shares of Spark Therapeutics in a report on Tuesday, May 8th. Finally, Barclays reiterated an “overweight” rating and set a $85.00 price objective (up from $64.00) on shares of Spark Therapeutics in a report on Wednesday, May 9th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $72.15.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Recommended Story: Risk Tolerance

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.